NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT07180459 2025-09-18
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
The First Affiliated Hospital of Zhengzhou University
Not yet recruiting
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06512467 2024-07-22
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05507632 2022-08-19
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting